Skoka Seeks FDA Approval for 55 Nicotine Products
The startup raised $21.5 million to bring a diverse portfolio of products to the U.S. retail market by 2027.
Updated on Oct. 30, 2026 in Startups
Live Poll
Should the government allow the retail sale of new nicotine pouch brands?
Skoka, a nicotine startup founded in 2024, has raised $21.5 million and submitted a bundled Premarket Tobacco Product Application (PMTA) to the FDA. The company plans to begin retail distribution of its products in the United States by 2027.
Why it matters
The company is moving to secure regulatory authorization for a wide portfolio of products before entering the U.S. market. This funding and submission signals an effort to establish a foothold in the nicotine industry by navigating the lengthy FDA approval process.
The firm submitted a bundled application covering 55 distinct products, which vary across 11 specific product varieties and five nicotine strengths. This comprehensive filing seeks regulatory clearance to serve the U.S. market for nicotine consumers aged 21 and older.
The players
Skoka
A nicotine startup founded in 2024 that targets adult users aged 21 and older.
Dan Aziz
The founder of Skoka.
The details
Skoka filed a bundled Premarket Tobacco Product Application (PMTA) to the FDA, which is the required regulatory path for new tobacco products to be legally sold in the United States. By bundling 55 products into a single submission, the company aims to establish a wide product range upon approval. The company is backed by capital from professional athletes and corporate executives, providing the financial runway to manage the regulatory development cycle through the planned 2027 launch.
Timeline
Skoka was established in 2024.
The company announced its funding and FDA submission on October 30, 2026.
Retail distribution in the United States is scheduled for 2027.
The Tech Race
Navigating the PMTA process is the primary competitive hurdle for any new entrant in the U.S. nicotine market. Skoka’s bundled submission places it among companies seeking broad regulatory approval to reach adult consumers at scale.
Consumers aged 21 and older will not see these products on store shelves until at least 2027. Availability will remain dependent on the FDA’s review timeline for the submitted bundled application.
The takeaway
Skoka is leveraging $21.5 million in early-stage capital to push a broad product portfolio through federal regulatory review. Industry observers should watch for updates on the FDA's decision regarding the bundled application, which will dictate the startup's 2027 retail launch feasibility.
What happens next
The company expects to launch U.S. retail distribution in 2027, pending the outcome of its pending FDA regulatory review.
Further reading
For broader trends in emerging business models, visit Startups.
Source note: This article includes information reported by Vcnewsdaily.
Live Poll
Should the government allow the retail sale of new nicotine pouch brands?
